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Effects of IGF-I on renal function in end-stage chronic
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Effects of IGF-I on renal function in end-stage chronic renal failure. To
determine whether insulin-like growth factor I (IGF-I) affects kidney
function in patients with end-stage chronic renal failure, we adminis-
tered recombinant human IGF-I (rhIGF-I) (100 pg/kg body wt subcu-
taneously twice daily) to nine individuals with baseline inulin clearances
below 21 ml/min/1.73 m2. Four patients were treated for four days
(short-term treatment) and five for periods between 13 and 27 days
(long-term treatment). Administration of rhIGF-I increased inulin clear-
ance, p-aminohippurate (PAH) clearance and the percent tubular reab-
sorption of filtered phosphate, and decreased plasma creatinine, blood
urea nitrogen (BUN) and plasma phosphate during short-term admin-
istration. Kidney volume was unchanged in patients receiving the
growth factor. rhIGF-I did not cause weight gain, proteinuria or
hypoglycemia. Inulin clearance was not increased significantly above
baseline after 13 or 20 days of IGF-I administration. PAH clearance
remained elevated after 13 days, but not after 20 days of IGF-I. Levels
of total circulating IGF-I were elevated above basal levels during the
entire course of long-term IGF-I administration. In contrast, levels of
circulating IGF binding protein 3 (IGFBP3) declined over time. Side
effects related to IGF-I forced discontinuation of its use in two of five
patients undergoing long-term treatment, and side-effects possibly
related to IGF-I prompted discontinuation of its use in two others. We
conclude that rhIGF-I can enhance glomerular filtration rate and renal
plasma flow when administered short-term to humans with end-stage
chronic renal renal failure. Further studies will be required to define its
efficacy and usefulness long-term.
Insulin-like growth factor I (IGF-I) is a proinsulin-like peptide
that exerts a variety of actions in the kidney [1]. Infusion of the
peptide in humans with normal renal function increases glomer-
ular filtration rate and renal plasma flow [2, 3]. Based upon data
generated in models of chronic renal failure in rats, it was
thought that the kidney was resistant to the effects of IGF-I to
enhance renal function in the setting of reduced functional renal
mass. However, we recently demonstrated that humans with
moderately-reduced renal function (inulin clearances between
22 and 55 mllmin/l.73 m2) do respond to short-term (4 days)
IGF-I administration by increasing their rates of glomerular
filtration and renal plasma flow. Our observations, although
preliminary, establish the potential for use of IGF-I as a
therapeutic agent in the setting of chronic renal failure [4].
Received for publication December 28, 1993
and in revised form February 16, 1994
Accepted for publication February 17, 1994
© 1994 by the International Society of Nephrology
The present studies were conducted to determine whether the
actions of IGF-I that we observed in patients with moderately-
reduced kidney function are manifest in individuals with end-
stage chronic renal failure. To this end, we administered
recombinant human insulin-like growth factor I (rhIGF-I) in a
fixed dose (100 pg/kg body wt twice daily) to nine individuals
whose baseline inulin clearances were less than 21 mlJminIl .73
m2, and evaluated its effects on inulin and p-aminohippurate
(PAH) clearances, on kidney volume, and on other parameters
of kidney function. One group of patients received rhIGF-I for
four days (short-term). A second group of patients was to be
administered the growth factor for 28 days (long-term). Our
data clearly demonstrate that rhIGF-I can increase glomerular
filtration rate and renal plasma flow when administered short-
term to patients with end-stage renal insufficiency. Further-
more, the growth factor is well-tolerated short-term. To our
knowledge, this represents the first demonstration that renal
function can be enhanced over a period of days by the admin-
istration of a pharmacological agent in the setting of end-stage
disease. However, the enhancements of the glomerular filtra-
tion rate and renal plasma flow induced by IGF-I short-term do
not persist during long-term administration and incidence of
side-effects is high. A strategy to tap the potential for use of
IGF-I long-term as a therapeutic agent for chronic renal failure
remains to be developed.
Methods
Individuals with end-stage chronic renal insufficiency, de-
fined as a creatinine clearance less than 20 mlImin/1 .73 m2, were
selected for the study. Patients with polycystic kidney disease,
a single kidney or a history of malignancy were excluded from
the study. Characteristics of the patients including baseline
inulin clearances are shown in Table 1.
The study protocol was approved by the Human Studies
Committee of Washington University. Patients were admitted
to the Washington University General Clinical Research Center
(GCRC) and placed on a 35 kcal/kg/day, 2 g sodium/day 0.8
g/kg/day protein diet. Subjects remained on the standardized
diet throughout the duration of the study.
Patients participated in either short-term (4 day) or long-term
(28 day) protocols. The first day of the protocols was designated
day 0. On day 0, measurements of blood urea nitrogen (BUN),
serum Na, K, HC03 creatinine, calcium and phosphate and
24-hour urinary excretion of calcium, phosphate and protein
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Table 1. Patient characteristics
Inulin
Patient Age/sex Diagnosis Medications clearance
I 58M Membranoproliferative
glomerulonephritis
Nifedipine XL
Clonidine
Furosemide
15.8
2 71F Hypertension Verapamil
Clonidine
Furosemide
7.8
3 59M Hypertension Nifedipine XL
Captopril
Isordil
5.1
4 40F Systemic lupus
erythematosus
Fosinopril
Furosemide
Prednisone
13.8
5 62M Diabetes
mellitus
Indapamide
Nicardipine
Furosemide
10.4
6 41M Nephritis Nifedipine
Pindolol
14.0
7 34M Henoch-
SchOnlein
Purpura
Nifedipine XL
Nadolol
13.8
8 37M Hypertension Nifedipine XL
Indapamide
Furosemide
20.6
9 43F Chronic
glomerulonephritis
Doxazosin
Diltiazem
Furosemide
10.4
10 73F Hypertension Enalapril
Amlodopine
Coumadin
13.6
were obtained in addition to inulin and PAH clearances and
spiral computerized tomographic examinations for determina-
tion of kidney volume. On days 1 through 4 for patients enrolled
for short-term protocols, or days 1 through 13 to 27 for patients
enrolled for long-term protocols, the subjects received rhIGF-I
(provided by Genentech Inc., South San Francisco, California,
USA) 100 sg/kg subcutaneously twice per day (8 a.m. and 8
p.m.). Inulin and PAH clearances were repeated on one or more
occasions during days 2 to 4 and when applicable on days 13, 20
and 27. Measurement of BUN, serum Na, K, HC03,
creatinine, serum calcium and phosphate, serum IGF-I and
IGFBP3, and urine calcium, phosphate and protein were ob-
tained on day 4. Measurements of kidney volume by spiral
computerized tomography were repeated on day 4. Blood
pressure, and pulse were measured four times daily, and
measurement of body weight was performed daily. In addition,
blood glucose was measured daily during the period of growth
factor treatment.
Patients were discharged from the GCRC following cessation
of IGF-I treatment, but remained on the standardized diet. The
patients returned 12 to 20 days post-discharge for follow-up
inulin and PAH clearances, measurements of BUN, serum
creatinine, calcium, phosphate and electrolytes, serum IGF-I
and IGFBP3, and spiral computerized tomographic measure-
ments of kidney volume.
BUN, serum Nat, K, HC03, creatinine, calcium, phos-
phate and glucose were measured on a Hitachi 747 autoanalyzer
(Boehringer Mannheim, Indianapolis, Indiana, USA). Urine
calcium and phosphate were measured on a Kodak E700
autoanalyzer (Eastman Kodak, Rochester, New York, USA).
Urine proteins were measured on a Technicon RA-XT Analyzer
(Indianapolis, Indiana, USA). Glomerular filtration rates and
rates of renal plasma flow were estimated by measurements of
inulin and PAH clearances as previously described [4]. Data
represent the means of three to four separate determinations
per study period. Radioimmunoassay for IGF-I was performed
in the core laboratory of the Washington University Diabetes
Research and Training Center for patients administered IGF-I
short-term as previously described [4]. For patients adminis-
tered IGF-I long-term, IGF-I and IGFBP3 levels in serum were
measured by Endocrine Sciences (Calabasas Hills, California,
USA). Tubular reabsorption of ifitered phosphate was calcu-
lated as described previously [4] using data obtained on days 0
and 4, and expressed as a percentage of the filtered load.
Computerized tomographic examinations and calculations of
renal volume were performed in the Mallinckrodt Institute of
Radiology (Washington University).
Three of the individuals with end-stage chronic renal failure
who had previously received IGF-I (patients 6, 7 and 8) and an
additional individual (patient 10) were readmitted/admitted to
the GCRC under conditions identical to those described above
and unknowingly received injections of vehicle for four days
instead of IGF-I.
Dunnett's multiple comparison procedure [5] was used for
multiple comparisons. Values were considered significantly
different if P < 0.05 for two-tailed analysis. Data shown in
Figure 1 were analyzed using one way analysis of variance
(ANOVA) (Instat, Graph Pad Software Inc., San Diego, Cali-
fornia, USA).
Results
We have shown previously that administration of 100 sg/kg
rhIGF-I, twice daily, to patients with moderate chronic renal
insufficiency increases inulin and PAH clearances progressively
over a four day period of time [4]. Similar observations were
made when rhIGF-I was given short-term to four patients with
end-stage chronic renal failure. Figure 1 illustrates clearances
expressed as % baseline levels. Baseline inulin and PAH
clearances were 10.6 2.5 and 58.7 12 mllmin/l.73 m2,
respectively. Each clearance was increased significantly over
four days of IGF-I administration (ANOVA) (Fig. 1). On day 4,
inulin clearance (14.0 2.6 inllminll.73 m2) was elevated 32%
above baseline and PAH clearance (75.3 17 ml/min/l .73 m2)
was increased 28% compared to baseline levels (P < 0.05 for
each comparison, Dunnett's multiple comparison procedure).
Filtration fractions ranged from 0.19 to 0.21 during days 0 to 4
(Fig. 1).
As was the case for patients with moderate chronic renal
failure [4], changes of inulin and PAH clearances in patients
with end-stage renal failure were accompanied by parallel
changes in levels of circulating IGF-I. During the days on which
IGF-I was administered, levels of IGF-I were elevated six- to
sevenfold over baseline in the four patients with end-stage
chronic renal failure. Following cessation of IGF-I administra-
tion, inulin and PAH clearances returned to levels that were not
different from baseline (Fig. 1) as before [4].
Administration of vehicle for four days to four patients with
end-stage chronic renal failure did not increase inulin or PAH
clearances. Values for inulin clearance were 16.5 2.1 and 13.0
1.6 mllminll .73 m2, respectively, on days 0 and 4 and values
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for PAH clearance were 75.3 23 and 67.8 16 mLlmin!l .73
m2 respectively.
Measurements of inulin and PAH clearance, BUN, serum
Nat, K, HC03, calcium, creatinine and phosphate were
obtained on a total of nine patients who received at least four
days of IGF-I treatment (patients ito 9). Values obtained prior
to treatment (Pre) were compared with those obtained following
four days of treatment (Rx) and those obtained 12 to 20 days
following cessation of IGF-I administration (Post). Treatment
with 100 j.g/kg rhIGF-I twice daily increased significantly inulin
and PAH clearances and decreased signficantly BUN, serum
creatinine and serum phosphate measured on days 4 compared
to values measured on day 0, consistent with improvement of
renal function. Serum HC03, and calcium were not changed
significantly. All values did not differ significantly from baseline
(day 0) when measured following cessation of IGF-I (Table 2).
Urine volume, calcium, phosphate and protein were not
significantly different on day 4 (Rx) of IGF-I administration
from values measured on day 0 (Pre). The percent tubular
rebsorption of filtered phosphate was significantly increased as
before [41 (Table 3).
Kidney volumes measured by spiral computerized tomogra-
phy on day 0 (289 45 cm3), day 4 (288 40 cm3) and following
cessation of IGF-I treatment (258 41 cm3) did not differ
significantly, one from the other.
Side effects of IGF-I experienced by patients ito 4 are listed
in Table 4. In none of these patients was any side effect of
sufficient severity to result in discontinuation of the growth
factor.
Five patients (patients 5 to 9) were enrolled in long-term
studies designed to delineate the effects of rhIGF-I adminis-
tered for 28 days. Baseline inulin and PAH clearances in these
five patients were 14.1 1.7 and 59.4 16 mlJminIl.73 m2,
respectively. The results of the long-term studies are shown in
Figure 2 which illustrates inulin and PAH clearances expressed
as the percent of baseline values. Only one of five patients
enrolled was able to complete a 28 day course of rhIGF. Growth
factor administration was discontinued because of side effects
in four others (discussed below). One patient (patient 5) who
lived outside of the St. Louis metropolitan area returned home
following cessation of IGF-I treatment to the care of his
referring physician, and was not able to return for follow-up
studies. A total of five patients received IGF-I for 13 days, three
IGF-I
.
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Parameters
(patients 1-9) Pre Rx Post
Inulin clearance 13.3 1.5 16.4 1.7k 12.5 1.3
mI/mm/I .73 m2
PAH clearance 59.1 9.8 76.0 13 57.1 11
mI/mm/I .73 m2
Serum Na mg/dl 139 1.2 138 1.1 139 1.5
Serum K mg/dl 4.2 0.2 4.1 0.2 4.4 0.2
Serum HC03 19.8 1.3 20.4 1.0 20.4 1.0
mEqi liter
BUN mg/dl 78.7 4.9 62.5 5.oa 75.5 5.5
Serum calcium 8.8 0.3 9.2 0.2 8.9 0.4
mg/dl
Serum creatinine 6.9 0.6 6.1 0.3a 6.9 0.6
mg/dl
Serum phosphate 5.0 0.3 4.5 0.3a 5.2 0.4
mg/dl
01234
Time, days
IGF-l
1
1
E1E:o.21
FU
0
Values were obtained on day 0, prior to IGF-I administration (Pre),
on day 4, during IGF-I administration (Rx), and post-discharge from the
GCRC (Post).
a Different from day 0, P < 0.05, Dunnett's multiple comparison
procedure
Table 3. Effect of IGF-I on urine parameters
0 1 2 3 4 FU
Time, days
Fig. 1. A. inulin clearances (vertical bars) and levels of serum IGF-I
(S) measured over time in patients 1 to 4. The time of administration of
IGF-I is indicated by the closed horizontal bar. Inulin clearances are
expressed as mean SE. Levels of IGF-I on day 0 were 0.8 0.2 U/mI.
B. PAH clearances (vertical bars) and filtration fractions (shown at
bases of vertical bars) in patients 1 to 4. PAH clearances are the means
SE. FU (follow-up).
Parameter
(patients 1—9) Pre Rx
Urine Volume ml/24 hr 3374 354 3174 353
Urine calcium mg/24 hr 44 13 39 9
Urine phosphate mg/24 hr 569 107 468 71
% Tubular reabsorption of 47.2 4.5 60.8 3.8a
filtered phosphate
Urine protein mg/24 hr 2558 817 2734 1174
Values were obtained on day 0, prior to IGF I administration (Pre) or
on day 4, during IGF I administration (Rx).
a Different from day 0, P < 0.0005, Student's t-test
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Patient
number Side effect
Days
encountered
Day
resolved
IGF-I
discontinued
1 None No
2 Jaw pain 3—4 5 No
3 None No
4 Jaw pain 2—4 5 No
5 Nasal congestion
Pericardial rub
8—20
20
22
22
Yes
6 Nasal congestion
Jaw pain
4-27
6—15
28
16
No
7 Bell's palsy 20 27 Yes
8
9
Nasal congestion
Jaw pain
Gingival
Hypertrophy
Nasal congestion
Pericardial rub
7—15
13—15
12—15
4—13
13
17
17
30
15
15
Yes
Yes
for 20 days and one for 27 days. Follow-up studies were
performed on four patients.
On day 4, inulin clearances (17.9 2.6 mllminJl.73 m2) were
elevated significantly above those measured on day 0 (P < 0.05,
Dunnett's multiple comparison procedure). However, inulin
clearances on day 13 (16.7 2.5 mlIminhl .73 m2) were no longer
elevated significantly, and those measured in the three patients
remaining in the study on day 20 were not significantly different
from inulin clearances measured in the same patients on day 0
(12.7 2.7 vs. 12.7 1.2 mlJminjl.73 m2, respectively).
PAH clearances measured on day 4 (78.6 24 mlIminIl .73
m2) were not elevated significantly above those measured on
day 0 for patients 5 to 9. However, PAH clearances were
elevated significantly above baseline for all nine patients (Table
2). PAH clearances measured on day 13 (80.0 22 mlimin/l .73
m2) were significantly greater than those measured on day 0 (P
<0.05, Dunnett's multiple comparison procedure). However,
PAH clearances measured for the three patients remaining in
the study on day 20 were not significantly different from values
obtained for those three patients on day 0(52.8 9.4 vs. 41.3
5.9 mlimin/1 .73 m2, respectively). Only patient 6 remained in
the study on day 27. His inulin and PAH clearances on that day
(14.0 and 52.0 mllmin/1.73 m2, respectively) were 100% and
140% of his baseline values. Inulin clearances measured on day
0 and at follow-up for the four patients who completed the
long-term study (14.0 1.1 vs. 15.0 1.9 mlIminIl.73 m2,
respectively) were not significantly different. Similarly, PAH
clearances measured at these times did not differ (65.0 19 vs.
63.7 21 mLlminll .73 m2, respectively). Filtration fractions
ranged from 0.21 to 0.24 during days 0 to 20 (Fig. 2).
Levels of circulating IGF-I measured in patients 5 to 9 were
elevated significantly above baseline on days 4, 13 and 20 (P <
0.01, P < 0.01, and P <0.05, respectively, Dunnett's multiple
comparison procedure). Levels measured on day 13 were not
significantly different from those measured on day 4. However,
levels measured on day 20 were lower than those measured on
day 4 (P < 0.05, Dunnett's multiple comparison procedure).
Levels measured at the time of follow-up studies were not
different from those measured on day 0. Levels of circulating
IGFBP3 measured on days 4, 13, and 20 were reduced signifi-
cantly from those measured on day 0 (P <0.01, P < 0.01 and P
100
Filtration
fraction //
T
,, 1://-#u
Days 0 4 1320
# Patients 5 5 5 3
Fig. 2. (A) Inulin clearances, (B) PAH clearances and filtration frac-
tions measured over time in patients 5 to 9. The number of patients
remaining in the study over time (# patients) is shown. Data are
expressed as in Figure 1.
< 0.05, respectively, Dunnett's multiple comparison proce-
dure). Levels of IGFBP3 measured at the time of follow-up
studies were not different from those measured on day 0 (Fig.
3). Circulating IGF-I and IGFBP3 levels in patient 6 were 236%
and 53% of his baseline values, respectively, on day 27.
All side-effects of rhIGF-I that were encountered in patients
ito 9, the day on which they were first reported, and the day on
which they resolved are listed in Table 4. Nasal congestion and
pain at the angles of the jaw (jaw pain) were the most frequent
side effects of IGF-I (4 of 9 patients each). Neither side effect
was of sufficient severity so that, in our judgment, administra-
tion of the the growth factor needed to be discontinued. Jaw
pain resolved in patients 6 and 8 while they continued to receive
IGF-I. In the other patients who developed jaw pain and in the
patients who developed nasal congestion, these side effects
Table 4. Side effects of IGF-I IGF-l
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Days 0
# Patients 5
[Lii
— 1/—lI- -1/-
Days 0 4 13 20 FU
#Patients 5 5 5 3 4
Fig. 3. Levels of total circulating IGF-I (A) and IGFBP3 (B) measured
over time in patients for whom data are shown in Figure 2. Data are
expressed as mean SE. Levels of IGF-I and IGFBP3 on day 0 were
192 13 ng/ml and 3.5 0.2 mg/liter, respectively.
resolved within two days of discontinuation of the growth
factor. More serious side effects of IGF-I that did prompt
discontinuation of the growth factor were development of Bell's
palsy (patient 7) and gingival hypertrophy (patient 8). The Bell's
palsy was completely resolved by seven days after stopping
IGF-I. Gingival hypertrophy was no longer present 15 days
after IGF-I was discontinued. Patients 5 and 9 developed
pericardial friction rubs during the course of IGF-I treatment.
We cannot be certain whether they were related to IGF-I or to
end-stage renal failure. At the time the rubs were noted the
inulin clearance of patient 5 was 8.0 mi/mm/I .73 m2 and of
patient 9 was 13.4 mllmin/l.73 m2. Therefore each could be
considered uremic. No patient experienced hypoglycemia, al-
terations in blood pressure, heart rate or experienced any
cardiac arhythmia at any time during the study. There were no
400)
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seizures, and margins of optic discs remained sharp during the
course of IGF-I administration to every patient.
Discussion
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It has been shown that continuous subcutaneous IGF-I
administration increases glomerular filtration rate and renal
plasma flow in humans with normal renal function [2, 3], and
enhances glomerular filtration rate and renal plasma flow in
patients with moderately-reduced renal function [4]. However,
to our knowledge, ours is the first demonstration that IGF-I
increases glomerular filtration rate and renal plasma flow in
humans with end-stage chronic renal insufficiency. The mean
percent increase in glomerular filtration rates observed in nine
patients with end-stage chronic renal insufficiency following
four days of IGF-I administration (23%) is comparable to that
observed in humans with normal renal function (29 to 30%) [2],
despite the administration of a higher dose of IGF-I to individ-
uals with normal kidney function (480 p.g/kg/day for 6 days)
than to patients with kidney failure (200 gIkg/day for 4 days).
The increments in levels of circulating IGF-I that resulted from
. administration of IGF-I to humans with normal renal function
(6- to 7-fold elevation) [2], were similar to those measured in the
patients with end-stage chronic renal failure (Fig. 1 and 3).
— Therefore, on the basis of comparing the response in normal
humans [2, 3] and in patients with end-stage chronic renal
failure, there is no evidence of renal resistance to the action of
IGF-I to enhance glomerular filtration rate or renal plasma flow
when administered short-term in the setting of severely-reduced
functional kidney mass. This is different from the resistance to
the action of GH [6, 7]. It is clear that renal functional reserve
remains in the setting of severe loss of renal function and that
the potential exists for the increase of the glomerular filtration
rate by medical means.
The studies of long-term IGF-I administration to patients
with end-stage chronic renal failure that are included in the
present report were conducted to ascertain whether the effects
of IGF-I to increase inulin and PAH clearances short-term (Fig.
1) are observed during longer-term IGF-I administration. Nei-
ther the action of IGF-I to enhance inulin clearance nor its
action to increase PAH clearance was manifest long-term (Fig.
2). Lack of persistence might be be explained by falling levels of
total circulating IGF-I (Fig. 3).
The dynamics of IGF-I interaction with sensitive tissues are
complex and incompletely understood. Biological activity of
circulating IGF-I is regulated by levels of plasma IGFBPs which
both enhance and inhibit IGF-I actions [8, 9]. In addition,
IGFBPs present in tissues regulate the interaction of circulating
IGF-I with its receptor. Tissue IGF-I receptor density is altered
by changes in levels of circulating IGF-I. In kidney, numbers of
IGF-I receptors are inversely related to levels of circulating
IGF-I [10].
Administration of rhIGF-I to patients with normal renal
function [9] or end-stage chronic renal failure (Fig. 3) results in
changes in at least one component of the IGF-I effector system
(reduced IGFBP3). It is possible that the lack of persistence of
the action of IGF-I to enhance glomerular filtration rate repre-
sents a refractoriness to IGF-I that results directly from this
change. Alternatively, the reduction in levels of circulating
IGFBP3 may reflect alterations in other components of the
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effector system such as down-regulation of renal IGF-I recep-
tors.
It is known that under some circumstances elevated levels of
circulating IGF-I are associated with or directly causative of
long-term changes in renal function. For example, the enhance-
ments of inulin and PAH clearances that accompany the eleva-
tions of circulating GH and IGF-I in patients with acromegaly
are sustained over years of time [11]. An increase in creatinine
clearance occurred within the first 12 days of IGF-I administra-
tion to a GH-insensitive Laron dwarf. The increase was pro-
gressive over the next 59 days [12].
GH stimulates the synthesis of IGFBP3 in liver [1, 8, 91. It is
the reduction in levels of circulating GH resulting from IGF-I
inhibition of pituitary GH release that is thought to result in the
fall of circulating IGFBP3 in humans administered IGF-I.
Concomitant administration of OH and IGF-I has been shown
to prevent the fall in circulating IGFBP3 and to enhance the
anabolic effects of each agent administered alone to humans [9].
Similarly, the combination of elevated OH and IGF-I levels in
acromegaly could permit the growth factor to enhance renal
function long-term by sustaining levels of IGFBP3 or modifying
some other component of the IGF-I effector system. Because of
their OH insensitivity, IGFBP3 levels are low and are increased
by lop-I in Laron dwarfs [13]. This difference or another
difference in the IOF-I effector system could explain the ab-
sence of refractoriness to IGF-I in these individuals.
It may be possible to prolong the duration of the increase in
inulin and PAH clearance induced by IGF-I by altering the
dosage of IGF-I or the timing of its administration so as to
prevent the change in levels of circulating IOF-I or in the
effector system. Alternatively, co-administration of GH with
IGF-I may reduce or eliminate the refractoriness that occurs
over time (Fig. 2).
The administration of IGF-I to experimental animals or to
humans has been reported to result in several side effects.
Hypoglycemia is dose-related [9] and was not observed in our
study. Tachycardia is a recognized side effect of IGF-I [14] and
was seen in association with its administration in one patient
with moderately-reduced renal function [4], but in none of the
patients included in the present study. Side effects of IGF-I
reported in other studies include Bell's palsy [IS], papiledema
[15], hypokalemia [15], and pain at the angle of the jaw [12, 14],
some of which our patients suffered (Table 4). As is the case for
hypoglycemia, the incidence of other side effects of IGF-I may
be reduced by decreasing the dose [9, 16].
Administration of rhIGF-I to indivduals with end-stage
chronic renal failure resulted in neither fluid retention nor
proteinuria. In contrast to the findings of Walker, van Wyk and
Underwood [12], rhIGF-I did not increase urinary calcium
excretion or urinary volume. As would be expected from its
effect to enhance the transport of phosphate across the proxi-
mal tubular brush border membrane [17], rhIGF-I increased the
percent tubular reabsorption of phosphate (Table 3). However,
hyperphosphatemia was not observed (Table 2).
One potential risk that could accompany the therapeutic use
of IGF-I in chronic renal failure is that of glomeruloscierosis
resulting from the hyperfiltration induced by this agent. Caution
is clearly indicated regarding its use in patients with dramati-
cally reduced renal function whose nephrons are already hy-
perfiltrating. Indeed, the decline in inulin and PAH clearances
that occurred following the initial increases after initiation of
IGF-I administration could be the result of hyperfiltration.
Evidence that growth-promoting agents may be glomerulo-
sclerotic comes from studies of rodent models of hypersoma-
totropism. Hypersomatotropic rats [18] and mice transgenic for
OH [19, 20] develop glomerulosclerosis. However, it is of
interest that mice transgenic for IGF-I with levels of circulating
IGF-I comparable to those in mice transgenic for OH do not
develop glomerulosclerosis [19, 20]. This finding is consistent
with the glomerulosclerotic action of GH in rodents being
mediated via a mechanism other than its action to increase the
synthesis and release of IGF-I.
Additional support for the safety of IGF-I or GH administra-
tion in humans may be derived from the observation that, in
contrast to the case in rodents, chronic renal failure is not a
complication of hypersornatotropism in humans. In fact, pa-
tients with long-standing acromegaly manifest marked renal
hypertrophy and have supranormal glomerular filtration rates,
suggesting that the hyperfiltration that accompanies long-stand-
ing elevations of circulating GH and IGF-I in humans is not
injurious to the kidney [11, 21].
Appendix. Abbreviations
ANOVA, analysis of variance; BUN, blood urea nitrogen; FU,
follow-up; GCRC, general clinical research center; GH, growth hor-
mone; IGF, insulin-like growth factor; IGFBP, insulin-like growth
factor binding protein; PAH, p-aminohippurate.
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